ArticleFrontiers in immunology2025
Comparing human pediatric immune responses to primary infection with dengue, chikungunya and Zika viruses.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Integrative Transcriptomic Analysis Reveals Distinct and Shared Host Responses in Dengue and Chikungunya Infections.International journal of molecular sciences · 2026Article
- Host-derived immune signatures as biomarkers to differentiate arboviral acute febrile illness from other causes of acute fever.Frontiers in microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The four dengue virus serotypes (DENV1-4), Zika virus (ZIKV) and chikungunya virus (CHIKV) have similar epidemiology and transmission cycles and are the most prevalent arthropod-borne viruses in humans, with half the world's population at risk of infection. Although these infections share overlapping clinical presentations, the immune mechanisms that distinguish these infections, particularly in children, remain poorly defined. We aimed to characterize the immune responses to DENV, ZIKV, and CHIKV in a pediatric population and to define the specific immune signatures associated with each virus. Methods: We characterized the immune responses to DENV, ZIKV and CHIKV by measuring cytokine/chemokine/growth-factor profiles in plasma/serum samples, and immune-cell profiles in peripheral blood mononuclear cells, collected from children during acute (~1-3 and ~4-6 days) primary infection with DENV1/DENV3 (n=32), ZIKV (n=50) or CHIKV (n=45), and during infection recovery (~14-25 days). Results: The innate immune responses to CHIKV and DENV were similar in terms of acute cytokine concentrations and monocyte frequencies. The innate immune response to ZIKV was mild, and the adaptive response was delayed, showing much lower concentrations of inflammatory cytokines and delayed T cell/B cell activation. Overall, the immune response to CHIKV and DENV were most similar than DENV and ZIKV, despite DENV and ZIKV belonging to the same flavivirus genus. The immune response to ZIKV was the most distinct, showing rapid B cell expansion but attenuated/delayed B cell activation. Conclusion: These findings reveal that early immune responses to arboviruses are defined more by infection-specific dynamics than by viral taxonomy, underscoring distinct immunological signatures for each virus.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.